Studying How Climate Disaster Responses Impact Post-NSCLC Surgery Survival

Commentary
Video

Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.

Leticia Nogueira, PhD, MPH, highlighted the next steps for researching response strategies for patients who undergo lung cancer surgery in the event of wildfires and other climate disasters. She spoke in the context of a study she published showing that patients who recovered from lung cancer surgery at facilities exposed to wildfires tended to have longer lengths of stay (LOS) compared with those who recovered at facilities without wildfire exposure.

Looking ahead, Nogueira, scientific director of Health Services Research at the American Cancer Society, stated that future work may focus on determining whether an extended LOS in the event of wildfire exposure may impact survival among patients who receive lung cancer surgery. Other priorities may include identifying optimal strategies for protecting patient health during wildfires and other climate disasters. According to Nogueira, proper response strategies may vary depending on the specific kind of climate disaster as well as a patient’s type of disease.

Findings from Nogueira’s study showed that among all patients in the study, the LOS was 7.45 days (SE, 0.22) for those who received surgery at facilities without wildfire exposure vs 9.42 days (SE, 0.25) among patients who underwent treatment at facilities exposed to wildfires (P <.0001).

Transcript:

The next steps for this specific patient population would be to test if staying in the hospital for a couple of additional days has an impact on survival. Does it make a difference? But similar to other disasters and other patient populations, what are any strategies that we can have to better protect the health and safety of these people during a disaster? Is it staying longer in the hospital? Is it helping the patient, the caregiver, and the support network to create a disaster preparedness plan and evacuation plan? Is it a patient transfer agreement? Is it a recommendation to wear a mask?

We do not know because we have not studied it. The next steps would be to prioritize this type of research and work together to figure out what works and what doesn’t work. It might be different things for different types of disasters. A wildfire might be different than a flood, and different patient populations. Lung cancer vs leukemia might be completely different.

Reference

Nogueira LM, Yabroff KR, Yates E, Shultz JM, Valdez RB, Nori-Sarma A. Facility exposure to wildfire disasters and hospital length of stay following lung cancer surgery. JNCI. Published online March 11, 2025. doi:10.1093/jnci/djaf040

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
4 experts in this video
4 experts in this video
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.